Last chance to submit your nominations for the FierceBiotech Innovation Awards
Applications are due this Friday, November 15th. Submit your nominations today.
Celgene of Summit, New Jersey, says that the FDA has accepted its NDA for Revlimid. Release
Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.
What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.
Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.